DCGI grants conditional market approval for Covishield & Covaxin
The Covishield vaccine is given in two doses, 84 days or 12-14 weeks apart. Doctors administer Covaxin in two doses, but they are 30 days apart.
New Delhi: Drugs Controller General of India (DCGI) on Thursday granted conditional market approval for Covishield and Covaxin, both homegrown vaccines that have driven India's vaccination programme.
Central Drugs Standard Control Organisation (CDSCO) has recommended for upgrade of covishield and covaxin status from restricted use in emergency situations to grant of new drug permission with conditions In adult population. The DCGI will evaluate the recommendations and give its decision.
Union Health Minister Dr Mansukh Mandaviya said, "The Central Drugs Standard Control Organisation (CDSCO) has now upgraded the permission for COVAXIN and Covishield from restricted use in emergency situations to normal new drug permission in the adult population with certain conditions."
"The conditions include supply for programmatic settings including registration on the CoWin platform and to continue to submit safety data on a six-monthly basis, added Mandaviya."
The Covishield vaccine is given in two doses, 84 days or 12-14 weeks apart. Doctors administer Covaxin in two doses, but they are 30 days apart.
As on 27th January, there are 22,02,472 active cases in India. The case positivity rate is at 17.75 per cent (in the last one week). 11 States have more than 50,000 active cases. Maharashtra, Karnataka and Kerala have more than 3 lakh active cases, according to the Ministry of Health.
